Longevica has completed a four-year, full-lifespan mammalian drug screen testing 1,033 compounds across 16,000 mice and identified two previously uncharacterized biological mechanisms linked to lifespan extension. The company has hired Prasun Mishra, a veteran of drug development at Genentech and the NIH with 12 programs in clinical trials and four regulatory approvals, as CEO to translate these findings into FDA-approvable therapeutics.
Key Points
- Full-lifespan mouse screen identified two novel aging mechanisms absent from prior literature.
- Mishra brings 30-program track record, 12 in clinical trials, 4 regulatory approvals.
- Company addresses translational gap between aging biology and disease-modifying drug development.
Longevity Analysis
The gap between identifying mechanisms that extend lifespan in animal models and developing drugs that clear regulatory approval has historically stalled geroscience. Longevica's dataset—generated across complete mammalian lifespans rather than short-term readouts or non-mammalian systems—provides empirical data on how compounds alter aging biology across interconnected organ systems. Mishra's appointment signals a strategic pivot from discovery to execution: converting empirical targets into therapeutics that target age-related metabolic dysfunction and fibrosis. This represents a material shift in how aging research moves toward clinical application, moving beyond retrospective data mining and computational modeling into formal preclinical validation and regulatory pathways.
Original published by Longevity.Technology, by Kyle Umipig.